Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) Director Bruce Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the completion of the sale, the director directly owned 360,682 shares in the company, valued at approximately $91,245,332.36. This trade represents a 1.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Stock Down 0.0%
Jazz Pharmaceuticals stock traded down $0.05 during trading on Wednesday, reaching $261.57. The stock had a trading volume of 695,963 shares, compared to its average volume of 953,015. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $265.05. The stock has a market cap of $16.43 billion, a PE ratio of -13,071.96, a P/E/G ratio of 0.22 and a beta of 0.32. The business has a 50 day moving average price of $239.98 and a 200 day moving average price of $207.93.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 35.03%. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.11 billion. During the same period in the prior year, the company posted ($8.25) earnings per share. The company’s revenue for the quarter was up 15.5% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.
Key Stories Impacting Jazz Pharmaceuticals
- Positive Sentiment: Jazz reported second-quarter revenue of approximately $1.21 billion, up 15.5% year over year and above the $1.11 billion consensus estimate. Management raised 2026 revenue guidance to roughly $4.6 billion-$4.75 billion, ahead of Wall Street expectations. Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
- Positive Sentiment: The core oxybate franchise remained resilient despite the full generic launch of Xyrem. Xywav revenue increased 13%, supported by 525 net patient additions, while Epidiolex revenue rose 16%. Strong demand across neuroscience and oncology was cited as a key driver of the outlook.
- Positive Sentiment: Investors are looking ahead to the potential expansion of Ziihera into first-line HER2-positive gastric and gastroesophageal junction cancer. The FDA’s decision is expected August 25, and approval could create a significant new revenue opportunity and accelerate growth. Jazz forecasts 2026 revenue as it prepares for zanidatamab PDUFA
- Positive Sentiment: Several analysts raised their price targets following the results: Needham to $292, Morgan Stanley and Baird to $280, and JPMorgan to $276. The firms maintained bullish ratings, reinforcing the market’s improving view of Jazz’s earnings and pipeline prospects.
- Neutral Sentiment: Jazz reported adjusted earnings of $5.71 per share, up sharply from a year-ago loss but below consensus estimates ranging from $6.04 to $6.18. The revenue beat and guidance increase outweighed the miss for many investors, but the earnings shortfall likely limited near-term upside.
- Negative Sentiment: Jazz plans to withdraw Zepzelca’s FDA application for second-line small-cell lung cancer, removing a regulatory and commercial opportunity in that indication and adding a negative element to an otherwise strong quarterly update. Jazz to withdraw Zepzelca application
Hedge Funds Weigh In On Jazz Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. USA Financial Formulas purchased a new position in Jazz Pharmaceuticals during the 1st quarter worth $25,000. Arista Wealth Management LLC purchased a new position in Jazz Pharmaceuticals during the second quarter worth about $241,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at about $61,000. GAMMA Investing LLC boosted its holdings in Jazz Pharmaceuticals by 18.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $339,000 after purchasing an additional 223 shares in the last quarter. Finally, Harbor Investment Advisory LLC increased its position in Jazz Pharmaceuticals by 349.2% during the 2nd quarter. Harbor Investment Advisory LLC now owns 292 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 227 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have issued reports on JAZZ shares. JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a report on Tuesday. Canaccord Genuity Group initiated coverage on shares of Jazz Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $290.00 price objective on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $287.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday. Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. Finally, Needham & Company LLC increased their target price on shares of Jazz Pharmaceuticals from $282.00 to $292.00 and gave the company a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $272.74.
View Our Latest Stock Analysis on JAZZ
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Featured Stories
- Five stocks we like better than Jazz Pharmaceuticals
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
